Teradyne (TER) CEO reports 554-share sale under 10b5-1 plan
Rhea-AI Filing Summary
Teradyne director and President & CEO Gregory Stephen Smith reported a sale of 554 shares of Teradyne common stock on 09/12/2025 at a price of $115 per share. The Form 4 shows 96,438.995 shares remained beneficially owned by Mr. Smith after the reported sale. The filing states the shares were sold under a sales plan adopted February 4, 2025 that was intended to comply with Rule 10b5-1, indicating the transaction followed a prearranged insider trading plan. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Positive
- Transaction disclosed promptly on Form 4 with specific date and price details
- Sale executed under a Rule 10b5-1 plan adopted February 4, 2025, indicating prearranged trades
- Clear post-transaction ownership reported as 96,438.995 shares
Negative
- Insider sale reported — 554 shares disposed, which may draw investor attention despite being modest
Insights
TL;DR Routine insider sale under a 10b5-1 plan by the CEO and director; disclosure aligns with standard governance practices.
The Form 4 documents a small, scheduled disposition of 554 shares at $115 each by Gregory Stephen Smith, who holds the roles of President & CEO and director. The explicit disclosure that the sale was executed pursuant to a 10b5-1 plan adopted on February 4, 2025 signals adherence to an established trading framework designed to avoid opportunistic insider trading. The remaining beneficial ownership is reported precisely as 96,438.995 shares, which provides clear post-transaction ownership visibility. From a governance perspective, this is routine and compliant, with no indications in the filing of ad hoc or opportunistic timing.
TL;DR A disclosed, modest insider sale that is unlikely to be material to Teradyne’s capitalization or signal company-specific issues.
The transaction size — 554 shares at $115 — represents a de minimis disposition relative to the reported post-sale holding of 96,438.995 shares. The use of a Rule 10b5-1 sales plan reduces interpretive ambiguity for investors about the motivation and timing of the sale. The filing contains the transaction date and price, the plan adoption date, and the signature date via attorney-in-fact, which together meet standard Form 4 disclosure norms. No derivative transactions or additional material events are disclosed in this filing.